Category Archives: Cf

Matt Hazlett/Getty Images North America via Zimbio

When Adam Eaton went down with a season-ending injury, Michael Taylor was called upon to play center field every day for the Washington Nationals. The team didnt really have any other choice other than Taylor. So far, he has done an admirable job filling in with exception to his plate discipline.

Since taking over full-time, Taylor has hit with (some) power and delivered on defense. His eye at the plate remains the Achilles heel in his offensive game.

Through his first 117 at-bats, Taylor has drawn only six walks. To make matters worse, he has a team-leading 44 strikeouts.

Poor plate discipline has been an issue throughout Taylors big league career. When the Nationals played him regularly in 2015, the now 26-year-old fanned an unacceptable 158 times. He struck out another 77 times last season in far fewer at-bats. If the Nationals didnt call up Trea Turner to play center field, Taylor would have surely fanned a lot more.

Through parts of four big league seasons, the Nationals center fielder is averaging 178 strikeouts per 162 games. He is also averaging only 35 base on balls per 162 games. As a result, he has a pitiful .283 OBP.

Taylors offensive abilities were already limited. Hes not the kind of player who appears capable of hitting for a high batting average. Players like this need to make up for it with an excessive amount of walks.

Young players striking out often and not getting on base via walks is contagious in the Nationals lineup. Turner has suffered the same fate. Its a problem for many MLB freshmen. The major difference between Taylor and Turner is the former has been consistently bad at this four several seasons. Turners high strikeout/low walk ratio is brand new.

No other season has been as important as this one for Taylors future. He barely cracked the Opening Day roster. With one outfield spot presumably open next year, he has a chance to increase his playing time exponentially.

To that same end, if the strikeouts persist and the walks stay absent, Taylor may forever lose his chance at starting regularly.

Tim Boyle is a Staff Writer for Outside Pitch MLB covering the Washington Nationals. Follow Tim on Twitter.

BaseballMichael TaylorMLBSportsWashington Nationals

Read the original here:

Washington Nationals: CF Michael Taylor still struggling with plate ... - OutsidePitchMLB

NY Stock News

CF Industries Holdings, Inc. (CF) Exposed Via Its Technical Chart NY Stock News CF Industries Holdings, Inc. (CF) has been having a set of eventful trading activity and it is clear from an examination of the charts that traders are now fully aware of the company's key metrics. A deeper exploration of the setup is sure to yield a ... and more »

See the rest here:

CF Industries Holdings, Inc. (CF) Exposed Via Its Technical Chart - NY Stock News

Introduction

Although fertilizer prices remain relatively weak, I do agree with the assessment of CF Industries' (NYSE:CF) management, which expects things to improve in 2018. This could indicate it's the right time to position yourself into the fertilizer companies in anticipation of higher prices. Whilst most American investors focus on the well-known mammoth companies like CF Industries, Agrium (NYSE:AGU) and Potash Corp. (NYSE:POT), I'd like to highlight one European fertilizer company as well, OCI (OTC:OCINF) (OTCQX:OCINY).

Some readers will remember the name, as CF Industries originally wanted to merge with this company and re-domicile itself in the UK and subsequently the Netherlands, but the deal ultimately fell through and CF Industries had to pay OCI a break fee.

CF Year to Date Price Returns (Daily) data by YCharts. OCI's main listing is on Euronext Amsterdam, where it's trading with OCI as its ticker symbol. The average daily trading volume is in excess of 600,000 shares for a dollar volume of approximately $14M. The current market capitalization is 4.61B EUR.

A brief overview of CF Industries' Q1

CF Industries saw its revenue increase by 3% to $1.04B, but unfortunately, its gross margin and operating income came in substantially lower as the pressure on its margins continued. This shouldn't be a surprise and even the net loss of $23 million (or 10 cents per share) was pretty much expected.

But just as in my previous articles I wrote about CF Industries, you should care more about the company's cash flows rather than the income statement as the depreciation rate ($205M in Q1) is substantially higher than the sustaining capex ($94M) to keep the plant and equipment in good shape.

Source: SEC filings

So whereas the company reported a net loss, its cash flow statements were actually showing a positive free cash flow. The adjusted operating cash flow was $234M, and after deducting the $94M in capex and the $54M distributed to non-controlling interests, the adjusted free cash flow was approximately $86M. Granted, that's still not great, but a FCF/share of $0.37 is definitely better than the net loss of 10 cents per share.

And what's perhaps even more important is the fact that the quarterly dividend was fully covered by the free cash flow in the first quarter. And that has been a while!

OCI only released a 'trading update', but the 2017 outlook is what matters

Dutch companies are only required to file financial reports on a half-year basis, so OCI only released a brief trading update, which actually sounded pretty positive. The utilization rate of its Egyptian urea facilities was approximately 100%, and the sales prices are increasing again compared to Q4.

This bodes well for the company's revenues, and as the new Iowa fertilizer plant has started to produce nitrogen and is the first greenfield factory built in almost three decades, I expect to see a substantial pick-up in the total sales volumes and revenue from the current quarter on, as this is the very first quarter wherein the new Iowa plant will start to contribute to the total result.

Source: OCI press release

Indeed, the company's capital expenditures will drop sharply to just $150-200M from this year on. Even if I would use the upper end of this guidance, OCI's free cash flow will increase tremendously from FY 2017 on, and I think the company will surprise a lot of investors. The recent strength in its share price shouldn't be a surprise, as the market is anticipating a windfall of cash flow in the 2017-2020 era, even at below-average fertilizer prices.

Comparing the metrics based on the 2016 results

Let's now put everything in perspective and compare some of the most important metrics of both companies. As OCI hasn't provided detailed financials after its first quarter, unfortunately, I will have to use the annual results of both companies. All amounts and numbers are in US Dollars.

As you can see, CF Industries scores better than OCI on the net debt/EBITDA metrics as well as the operating cash flow margin. However, I do expect OCI's EBITDA and operating cash flow to increase faster in 2017-2018, as the company has completed its Iowa nitrogen facility and is in the final construction phase of the Natgasoline site (methanol) which should be completed by the end of this year.

On top of that, OCI's board has sanctioned the re-start of the second production line at BioMCN to increase its methanol production even further. This shouldn't be surprising as the methanol price has been booming lately, as you can see in the next image:

Source: OCI Trading update

The 430,000 tonnes of Methanol in Europe will add at least $150M to the revenue, whilst the 875,000 tonnes of methanol produced in Texas at the Natgasoline facility will add an additional $310-340M per year. This means OCI will see its revenue increase by $500M based on these projects alone, and this could push the EBITDA to in excess of $600M (this still excludes the contribution from the new Iowa plant, the higher commodity prices and the lower interest expenses). Throw in the $100M in annual cost savings that has been identified, and OCI is ready to flex its muscles.

Investment thesis

So whilst CF Industries seemed to be scoring better based on the 2016 results, investing is about looking to the future. I'm particularly pleased to see that OCI is now planning to use pretty much its entire free cash flow to reduce its net debt in order to obtain an investment grade rating by 2018-2019. I would expect the net debt to drop below $4B by the end of this year, and to less than $3.5B by the end of 2018.

Considering OCI's cost of debt is really high (it's a non-investment grade issuer) at 5.25% ($242M in interest expenses divided by $4.6B gross debt), reducing the net debt will have a huge impact on its interest bill and free cash flow. A positive snowball effect, that's for sure.

Investing in CF Industries and in OCI isn't a mutually exclusive scenario, and a combination of both companies might cover your needs. CF Industries will act as the dividend payer whilst OCI is focusing on repairing its balance sheet to get an investment grade rating. It still is a pity the merger didn't go through, as the combination of both companies and OCI's renewed investments in Methanol would have resulted in a strong conglomerate.

And before we leave: Consider joining European Small-Cap Ideas to gain exclusive access to actionable research on appealing European-focused investment opportunities, and to the real-time chat function to discuss ideas with similar-minded investors!

Disclosure: I am/we are long CF, AGU, OCINF.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

See the original post:

Should You Buy CF Industries Or OCI? - Seeking Alpha

Forbes

How Reg CF Closes the Financing Gap for Women Entrepreneurs Forbes The small businesses financing gap. Many small businesses struggle to get the funding they need. In fact, 60% had a financing shortfall, meaning they received less than the amount they applied for, according to 2016 Small Business Credit Survey: Report ...

Read the original post:

How Reg CF Closes the Financing Gap for Women Entrepreneurs - Forbes

Wall Street Journal (subscription)

CF Corp to Buy Fidelity & Guaranty Life Wall Street Journal (subscription) An acquisition company created by a former Blackstone Group L.P. partner and Fidelity National Financial Inc.'s chairman reached a deal Wednesday to buy life insurance provider Fidelity & Guaranty Life in an all-cash deal worth about $1.84 billion. CF ... CF Corp. to Buy Fidelity & Guaranty for $1.8 Bln (CFCO, FGL)Investopedia CF Corporation to Acquire Fidelity & Guaranty Life in Transformative All-Cash Transaction Valued at $1.835 BillionPR Newswire (press release) CF Corp to acquire Fidelity & Guaranty Life for about $1.84 blnNasdaq Reuters -The Insurance Insider (subscription) -Benchmark Monitor -Zacks all 84 news articles »

See the rest here:

CF Corp to Buy Fidelity & Guaranty Life - Wall Street Journal (subscription)

Preparations are in full swing for the takeoff of the revamped Community Charity Airshow on Aug. 30 at the Brantford Municipal Airport.

In a transition year, the Canadian Warplane Heritage Museum in Hamilton has stepped in to run the show with help from the Rotary Club of Brantford, which last November announced that it was stepping away from organizing the annual event. The club took over sponsorship of the show from the Brant United Way in 2009.

The transition of the show's organization to the museum from Rotary has been seamless, the event's co-chairs Sherry Kerr, Rotary president, and Dave Rohrer, president and CEO of the museum, said at a media reception on Thursday morning at the museum, where they highlighted details of the fundraising event.

This year's show will features several museum aircraft, including the Avro Lancaster - making Brantford its only airshow appearance of the 2017 season. Other highlights include the Canadian Forces Snowbirds and a demonstration of a CF-18 decorated in a striking paint scheme based on the official Canada 150 logo.

"It's a great relationship from the start," said Kerr.

"They are able to provide us with some great aircraft for people to view on the tarmac. And getting the legendary Lancaster bomber is a big plus," she said.

Rohrer said the museum is "thrilled to be part of this great community event that raises funds for local children.

"We have participated in the Brantford shows for many years and have seen the enthusiasm from the crowds. To be able to help continue that magic is an honour for us, and we hope to make the community proud.

"The show is a real gem."

Also at Thursday's announcement was RCAF Capt. Matthew "Glib" Kutryk, who will fly the Canada 150 CF-18 in shows across the country, including in Brantford.

"I feel like the luckiest guy in the air force to be able to fly this plane," Kutryk said in an interview.

"My goal has always been to fly a CF-18. To get to fly the Canada 150 CF-18 is a great high. It's the prettiest bird in the fleet."

He explained that the Canada 150 logo forms foundation of the overall design. The stylized maple leaf has 13 points shaped as diamonds, the celebratory gem. Four points represent Confederation's original provinces - Ontario, Quebec, New Brunswick and Nova Scotia - and the other nine are for the six other provinces and three territories.

The rest of the design plays off the logo.

The logo was designed in 2014 by Ariana Cuvin, then a global business and digital arts student at the University of Waterloo. The CF-18's paint job was designed by Jim Belliveau of 4 Wing Cold Lake.

"Seeing this incredible jet in person has made me even more motivated to share it with Canadians," Kutryk said when the painted aircraft was unveiled in April.

"I hope that this jet will inspire all Canadians to chase their dreams as I did, because that is what Canada is all about."

Kutryk explained Thursday that paint job means that. when the pilot flips the plane over in midflight, spectators suddenly will see an explosion of red and white.

"This is a unique paint job," Kutryk said. "We will never see one that good again."

The name "Glib" is not a nickname, It is Kutryk's call sign when he flies. It's a tradition in the RCAF going back to the First World War. Once a pilot flies a first mission, the call sign sticks with that person for the rest of the career.

Kutryk's said he flew several times with the ISIS Mission in Iraq and Syria.

He will fly in 25 shows across Canada this year, for a total 55 performances because some events have multiple flights.

On the other side of the museum's display space, a mechanics were working on various parts of the Lancaster, ensuring it will be ready for the Brantford show.

The show's format remains the same as in past years. On Aug. 29 there will be a fundraising dinner with the pilots present. The show runs on Aug. 30.

The event is free with a request for a voluntary donation at the entrance.

Parking costs $20.

MMarion@postmedia.com

Twitter.com/EXPMarion

Brantford Expositor 2017

Originally posted here:

CF-18 pilot 'luckiest guy' - Brantford Expositor

CF Industries Holdings, Inc. (CF - Free Report) has been disappointing investors of late, given that the shares of this nitrogenous fertilizer manufacturer and distributor have recorded a negative return of 9.7% year-to-date. Moreover, the company has a long term estimated earnings growth rate of -1.23%.

Should investors dump this stock from their portfolio? Lets find out.

Estimates Moving South

Estimates for the company for second-quarter 2017, fiscal 2017 and fiscal 2018, have moved south in the past 30 days, reflecting the negative outlook of analysts. For the second quarter, estimate has plunged 82.6% from 23 cents to 4 cents per share in the past 30 days.

For fiscal 2017, the estimate has dropped from earnings of 25 cents to a loss of 23 cents. For fiscal 2018, the estimate has declined 42.2% to 52 cents per share.

Negative Earnings Surprise History

CF Industries missed the Zacks Consensus Estimate in the last reported quarter, recording a negative surprise of 44.4%. In the trailing four quarters, the company posted an average negative earnings surprise of 121.5%.

Disappointing Q1

CF Industries posted a loss of $23 million or 10 cents per share in first-quarter 2017, as against a profit of $26 million or 11 cents recorded a year ago. Barring one-time items, adjusted earnings came in at 5 cents per share for the quarter, compared with the year-ago figure of 43 cents. Earnings missed the Zacks Consensus Estimate of 9 cents.

Price Performance

CF Industries stock has lost around 1.8% in the past one year, underperforming the Zacks categorized Fertilizerssub-industrys 2% gain.

Persistent Headwinds

CF Industries continues to bear the brunt of pricing pressure. Urea prices have been under pressure due to higher nitrogen supply. High supply levels in the global nitrogen market due to capacity additions pressured pricing in the last reported quarter.

Unfavorable Zacks Rank & Score

CF Industries currently carries a Zacks Rank #5 (Strong Sell) and a VGM score of F. Here 'V' stands for Value, 'G' for Growth and 'M' for Momentum. CF Industries score is a weighted combination of these three scores (Value - B, Growth - A, Momentum - B). Such a score allows investors to eliminate the negative aspects of stocks and select winners.

Key Picks Some better-ranked stocks in the basic materials space include Kronos Worldwide Inc. (KRO - Free Report) , ArcelorMittal (MT - Free Report) and The Chemours Company (CC - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of todays Zacks Rank #1 stocks here.

Kronos has an expected long-term earnings growth of 5%.

ArcelorMittal has an expected long-term earnings growth of 11.4%.

Chemours Company has an expected long-term earnings growth of 15.5%.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>

Continued here:

Why Should You Dump CF Industries (CC) from Your Portfolio ... - Zacks.com

YONKERS, NY--(Marketwired - May 25, 2017) - ContraFect Corporation(NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the initiation of an international Phase 2 study evaluating its first-in-class lysin, CF-301, as a potential treatment of Staphylococcus aureus (Staph aureus) bacteremia including right sided endocarditis. Staph aureus bacteremia and endocarditis are serious life threatening infections, associated with substantial morbidity and mortality despite currently available conventional antibiotics. This multicenter, randomized, double-blind, placebo-controlled study is designed to evaluate the potential for CF-301 to be used in addition to standard-of-care (SOC) antibiotics to significantly improve clinical success rates compared to SOC antibiotics alone. Safety, tolerability, and pharmacokinetics of CF-301 will also be evaluated in the study. The company expects to announce top line results in Q4 2018.

"We are very pleased to initiate the first clinical study of CF-301 in patients with S. aureus bacteremia. Based on the extensive amount of pre-clinical data generated, CF-301 has the potential to improve clinical outcomes for these patients by rapid bacterial killing, synergy with conventional antibiotics and clearance of biofilms that complicate Staph aureus infections, " said Cara Cassino, M.D., EVP of Research and Development and Chief Medical Officer at ContraFect.

"We are excited about the initiation of this trial, and the promise that CF-301, and potentially other lysins in our pipeline, may offer important new advances in the treatment of bacterial infections which are a global health care threat," said Steven C. Gilman, Ph.D., Chairman of ContraFect.

In the United States alone, there are approximately 120,000 cases annually of the bloodstream infection Staph aureus bacteremia, which causes approximately 30,000 deaths. Staph aureus bacteremia can be further complicated when the infection spreads into the heart muscle, heart valves or lining of the heart, causing endocarditis. Even with current SOC antibiotic therapy, the resulting damage to the heart muscle or heart valves could require surgery for definitive treatment to prevent stroke, heart failure or multi-organ system damage. Of further concern, drug-resistant strains of Staph aureus are now evolving additional resistance against SOC antibiotics, which may ultimately result in an increase in the number of cases and in mortality from Staph aureus bacteremia, including endocarditis.

About the Trial:

ContraFect plans to conduct the trial in approximately 70 sites worldwide including North America, South America, and Europe. A total of 115 patients are expected to be enrolled, randomized 3:2 to receive either a single dose of 0.25 mg/kg CF-301 administered via a 2 hour IV infusion in addition to SOC antibiotics or placebo plus SOC antibiotics.

The primary endpoint of the trial is early clinical response. In addition, safety, tolerability, pharmacokinetics, and a number of exploratory clinical and health resource utilization endpoints will be evaluated.

More information about the trial is available at http://www.clinicaltrials.gov.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staphylococcus aureus) and influenza.

About CF-301:

CF-301 is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staph aureus, a major cause of blood stream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staphylococcus aureus (Staph aureus) bacteremia. It has a novel, rapid, and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm infections. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect. It is the first lysin to enter clinical studies in the U.S.

FORWARD-LOOKING STATEMENTS

This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding our ability to discover and develop protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, including whether CF-301 has the potential to be a first-in-class lysin therapeutic for the treatment of Staph aureus bacteremia including right sided endocarditis, whether CF-301 used in addition to SOC antibiotics can significantly improve clinical success rates compared to SOC antibiotics alone, whether CF-301 can improve clinical outcomes for patients by rapid bacterial killing, synergy with conventional antibiotics and clearance of biofilms which complicate Staph aureus infections, whether CF-301 and other lysins in our pipeline will offer important new advances in the treatment of bacterial infections which are a global health care threat, our plans to conduct the trial in approximately 70 sites worldwide including North America, South America, and Europe, our ability to enroll a total of 115 patients, whether we achieve our clinical endpoints, the announcement of top line results in Q4 2018 and our ability to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases and those detailed under the caption "Risk Factors" in ContraFect's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 and its other filings with the Securities and Exchange Commission. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View original post here:

ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia - Markets Insider

Subscribe today for full access on your desktop, tablet, and mobile device.

370

Let friends in your social network know what you are reading about

Gose threw an inning for the Flying Tigers against Class A Palm Beach, allowing one run on one hit with one strikeout and one walk.

Try Another

Audio CAPTCHA

Image CAPTCHA

Help

CancelSend

A link has been sent to your friend's email address.

A link has been posted to your Facebook feed.

Free Press sports writer Anthony Fenech, reporting from his hotel in Houston, examines the Tigers as they prepare for their 11-game, 10-day road trip.

Detroit Tigers outfielder Anthony Gose takes part in drills during spring training Monday, Feb. 20, 2017, in Lakeland, Fla.(Photo: Kirthmon F. Dozier, Detroit Free Press)

HOUSTON Anthony Gose was assigned to Class A Lakeland on Monday.

He was listed as a left-handed pitcher, not a centerfielder, and made his professional baseball debut as a pitcher later in the night.

Gose threw an inning for the Flying Tigers against Class A Palm Beach, allowing one run on one hit with one strikeout and one walk.

After pitching for the first two months of the season in extended spring training, Gose finally got his first taste of game action. According to a tweet from Lakeland assistant general manager Dan Lauer, Gose hit 99 m.p.h.

The Tigers are very optimistic with Goses progress throughout extended spring training, according to vice president of player development Dave Littlefield.

Gose is not playing centerfield any longer, Littlefield said.

Gose, 26, is a lifetime .240 hitter in parts of five big-league seasons. He was acquired in a trade with the Blue Jays for second baseman Devon Travis prior to the 2015 season.

Contact Anthony Fenech: afenech@freepress.com. Follow him on Twitter @anthonyfenech.

1:06

1:25

1:36

1:00

0:58

1:06

1:16

1:06

1:01

1:48

View original post here:

Detroit Tigers ex-CF Anthony Gose hits 99 m.p.h. in pro pitching ... - Detroit Free Press

This is a great article available only to our subscribers

CLICK HERE TO LOGIN OR SUBSCRIBE BELOW

C.F. Choral Program Academic Achievement Award winners Thirty-seven members of the Camden Fairview High School Choral Program were presented Academic Achievement Awards for having 3.0 GPAs or above by the Arkansas Choral Directors Association following their spring concert earlier this month. Receiving recognition were, front row, from left, Maggie Smith, Bailey Passmore, Melanie King, Elijah McCarver, Mallory Jeffus, Summer Shipp, Ariel Williams, and Gabrielle Williams. Second row, Trinity Thompson, Alexia Easter, Hope Hesterly, Kyla Frazier, Ayana Bigby, Mya Arnold, Sierra Leconte, Jasmine Davis, Beyonce Rogers, Peyton Ruch and AnnaLisa VanAssche. Back row, Alexis Carrol, Madison Jeffus, Emily D'mitruchina, Atlanta Brown, Tianna Johnson, Callie Blair, Darnisha Tooks, Jaqualen Williams, Maurice Jackson, Dustin Mills, Treyveon Pace, Knorjia Tooks, DJ Sherman. Not pictured are Kaylin Browning, AJ Rogers and Kealeigh Shelton. Cynthia Outlaw is the director of choral department.

Get started in less than 60 seconds. Pick a plan below to sign up.

Stay InformedKnow more about whats going on in your neighborhood, Camden and Ouachita County, our surrounding area, Arkansas, the nation, and the world.

Save MoneyThousands of dollars in savings every day with deals from our local advertisers.

Be EntertainedFrom movies and arts to sports and things to do on the weekend, you'll never miss out on great events and entertainment.

Available all the timeRead when you want, how you want. Access all of our coverage in print, online, on your smartphone or on your tablet computer with your subscription.

Smart DecisionsReading the newspaper gives you information that helps you make smart decisions for you and your family. Subscribing to the newspaper is an investment in yourself.

More here:

CF Choral Program Academic Achievement Award winners - Camden News